Your browser doesn't support javascript.
loading
Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden-an update on incidence and first prevalence estimate.
Stamatis, Pavlos; Turkiewicz, Aleksandra; Englund, Martin; Turesson, Carl; Mohammad, Aladdin J.
Afiliação
  • Stamatis P; Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden.
  • Turkiewicz A; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Greece.
  • Englund M; Department of Clinical Sciences Lund, Clinical Epidemiology Unit, Sweden.
  • Turesson C; Department of Clinical Sciences Lund, Clinical Epidemiology Unit, Sweden.
  • Mohammad AJ; Department of Clinical Sciences Malmö, Rheumatology, Lund University, Sweden.
Rheumatology (Oxford) ; 61(1): 146-153, 2021 12 24.
Article em En | MEDLINE | ID: mdl-33742665
OBJECTIVE: To characterize the epidemiology of temporal artery biopsy-positive (TAB+) GCA, including trends in incidence, seasonal variation and prevalence in Skåne, the southernmost region of Sweden. METHODS: All histopathology reports of TABs from 1997 through 2019 were reviewed to identify patients diagnosed with TAB+ GCA. Incidence rates based on the 23-year period and the point-prevalence at 31 December 2014 were determined. An alternative prevalence calculation included only TAB+ GCA patients living in the study area and receiving immunosuppressant therapy on the point-prevalence date. RESULTS: One thousand three hundred and sixty patients were diagnosed with TAB+ GCA (71% female). The average annual incidence 1997-2019 was 13.3 (95% CI: 12.6, 14.0) per 100 000 inhabitants aged ≥50 years and was higher in females (17.8; 95% CI: 16.7, 18.9) than in males (8.2; 95% CI: 7.4, 9.0). The age- and sex-standardized incidence declined from 17.3 in 1997 to 8.7 in 2019, with incidence ratio (IR) of 0.98 per year (95% CI: 0.98, 0.99). A seasonal variation was observed with higher incidence during spring than winter [IR = 1.19 (95% CI: 1.03, 1.39)]. The overall point-prevalence of TAB+ GCA was 127.1/100 000 (95% CI: 117, 137.3) and was 75.5 (95% CI: 67.7, 83.3) when including only patients receiving immunosuppressants. CONCLUSION: Over the past 2 decades, the incidence of biopsy-confirmed GCA has decreased by ∼2% per year. Still, a high prevalence of GCA on current treatment was observed. More cases are diagnosed during spring and summer than in the winter.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes Tipo de estudo: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes Tipo de estudo: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article